Nedaplatin(Synonyms: NSC 375101D)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Nedaplatin (Synonyms: NSC 375101D) 纯度: ≥98.0%

Nedaplatin (NSC 375101D) 是顺铂衍生物和DNA损伤剂。

Nedaplatin(Synonyms: NSC 375101D)

Nedaplatin Chemical Structure

CAS No. : 95734-82-0

规格 价格 是否有货 数量
10 mg ￥810 In-stock
50 mg ￥3096 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Nedaplatin 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus

生物活性

Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.

体外研究
(In Vitro)

Nedaplatin (NSC 375101D, NDP) is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter concentrations[1]. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (NSC 375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

303.18

Formula

C2H6N2O3Pt
CAS 号

95734-82-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。
溶解性数据
In Vitro: 

H2O : 13.6 mg/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatin’s activity)

DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin’s activity)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2984 mL 16.4919 mL 32.9837 mL
5 mM 0.6597 mL 3.2984 mL 6.5967 mL
10 mM 0.3298 mL 1.6492 mL 3.2984 mL

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。
参考文献

  • [1]. Kanzawa, F., et al., In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res, 2001. 7(1): p. 202-9.

    [2]. Uchida, N., et al., Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer, 1998. 34(11): p. 1796-801.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务